脑啡肽酶抑制剂治疗心力衰竭及高血压的研究进展被引量：3

下载PDF

导出

摘要心血管疾病(cardiovascular disease,CVD)仍然是世界各地人群发生率、病死率升高的主要原因。目前药物治疗尚不能十分有效地阻止疾病进展,这反映出对疾病机制的认识不全面,仍需要扩大对药物治疗的研究。CVD中最严重的疾病——心力衰竭(heart failure,HF)及高血压,与神经激素系统的过度激活有关,例如肾素-血管紧张素-醛固酮系统(renin-angiotensin-aldosterone system,RAAS)。目前为止,RAAS拮抗剂依然是治疗HF及高血压最有效的治疗方法。近年来金属肽酶脑啡肽酶(neprilysin,NEP)受到广泛研究。然而,单独的肽酶脑啡肽酶抑制剂(neprilysin inhibitor,NEPI)治疗不如标准化药物效果好。但近期新型NEPI联合药物力求充分发挥血管紧张素转化酶抑制剂(angiotensin-converting enzyme inhibitor,ACEI)和NEPI介导排尿利钠的临床疗效,并改善临床安全性,因而受到国际广泛关注。

作者步睿吴建军贾静韦宏陈延军

机构地区哈尔滨医科大学附属第四医院

出处《医学研究杂志》 2015年第12期12-14,共3页 Journal of Medical Research

基金黑龙江省自然科学基金面上项目(D201101)

关键词脑啡肽酶抑制剂肾素-血管紧张素-醛固酮系统心力衰竭高血压

分类号 R544 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献18

1Formentini I,Bobadilla M, Haefliger C, et al. Current drug develop- ment challenges in chronic kidney disease ( CKD)-identification of individualized determinants of renal progression and premature cardio- vascular disease (CVD) [ J ]. Nephrol Dial Transplant, 2012 , 27 (Suppl 3) :81 -88.
2Jhund PS, Macintyre K, Simpson CR,et al. Long -term trends infirst hospitalization for heart failure and subsequent survival between 1986 and 2003 :a population study of 5,1 million people [ J ]. Circulation, 2009,119(4) :515 -523.
3von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protec- tion in large scale trials [ J]. Cardiovasc Drugs Ther, 2013,27 ( 2 ) : 171 - 179.
4Dive V, Chang CF, Yiotakis A, et al. Inhibition of zinc metallopepti- dases in cardiovascular disease-from unity to trinity, or duality?E J ]. Curt Pharm Des ,2009,15 (31 ) :3606 - 3621.
5Campbell DJ. Vasopeptidase inhibition: a double- edged sword? [ J]. Hypertension ,2003,41 (3) :383 -389.
6Potter LR. Natriuretic peptide metabolism, clearance and degradation I J]. FEBS J,2011,278(11) :1808 - 1817.
7Sangaralingham SJ, Heublein DM, Grande JP, et al. Urinary C -type natriuretic peptide excretion: a potential novel biomarker for renalfi- brosis during aging [ J ]. Am J Physiol Renal Physiol, 2011,301 ( 5 ) : 943 - 952.
8Weber MA. Vasopeptidase inbibitors [ J ]. Lancet, 2001,358 ( 9292 ) : 1525 - 1532.
9Kostls JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial [ J ]. Am J Hypertens ,2004,17 ( 2 ) : 103 - 111.
10Hegde LG, Yu C, Renner T, et al. Concomitant angiotensin AT1 re- ceptor antagonism and neprilysin inhibition produces omapatrilat - like antihypertensive effects without promoting tracheal plasma extravasa- tion in the rat[ J]. J Cardiovasc Pharmacol,2011,57(4) :495 -504.